Financial Contrast: PTC Therapeutics (PTCT) versus Its Rivals
PTC Therapeutics (NASDAQ: PTCT) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare PTC Therapeutics to similar companies based on the strength of its earnings, risk, institutional ownership, analyst recommendations, valuation, dividends and profitability.
This table compares PTC Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|PTC Therapeutics Competitors||-5,311.45%||-433.95%||-39.53%|
Institutional and Insider Ownership
86.2% of PTC Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.1% of PTC Therapeutics shares are owned by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares PTC Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|PTC Therapeutics||$82.71 million||-$142.11 million||-5.80|
|PTC Therapeutics Competitors||$284.28 million||$34.29 million||80.89|
PTC Therapeutics’ rivals have higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings and target prices for PTC Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|PTC Therapeutics Competitors||852||3199||11602||231||2.71|
PTC Therapeutics presently has a consensus target price of $18.14, indicating a potential upside of 8.32%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.40%. Given PTC Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics has less favorable growth aspects than its rivals.
Volatility and Risk
PTC Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, PTC Therapeutics’ rivals have a beta of 6.97, meaning that their average share price is 597% more volatile than the S&P 500.
PTC Therapeutics rivals beat PTC Therapeutics on 8 of the 12 factors compared.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.